Holen Sie sich die Stockscreener-App
6.09
2.01%
0.12
Schlusskurs vom Vortag:
$5.97
Offen:
$5.94
24-Stunden-Volumen:
4.39M
Relative Volume:
1.62
Marktkapitalisierung:
$898.31M
Einnahmen:
$204.73M
Nettoeinkommen (Verlust:
$-184.29M
KGV:
-8.4279
EPS:
-0.7226
Netto-Cashflow:
$-51.87M
1W Leistung:
+0.83%
1M Leistung:
+19.88%
6M Leistung:
+54.96%
1J Leistung:
+110.73%
1-Tages-Spanne:
$5.83
$6.11
1-Wochen-Bereich:
$5.67
$6.11
52-Wochen-Spanne:
$1.99
$6.55
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Firmenname
Maravai Lifesciences Holdings Inc
Sektor
Branche
Telefon
(858) 546-0004
Adresse
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
6.09 | 898.31M | 204.73M | -184.29M | -51.87M | -0.7226 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | Eingeleitet | Guggenheim | Neutral |
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-08-08 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Herabstufung | Goldman | Buy → Neutral |
| 2023-01-05 | Herabstufung | UBS | Buy → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-11-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Eingeleitet | Credit Suisse | Outperform |
| 2020-12-15 | Eingeleitet | Goldman | Buy |
| 2020-12-15 | Eingeleitet | Jefferies | Buy |
| 2020-12-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-12-15 | Eingeleitet | Stifel | Buy |
| 2020-12-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-14 | Eingeleitet | UBS | Buy |
Alle ansehen
Maravai Lifesciences Holdings Inc Aktie (MRVI) Neueste Nachrichten
Form 4 Maravai Lifesciences Holdings Inc For: 10 July By Investing.com - Investing.com Nigeria
Maravai Lifesciences (MRVI) CEO reports 29,250-share tax withholding event - Stock Titan
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032 - AOL.com
Maravai LifeSciences(MRVI) Stock Options Chain | Quotes & News - Moomoo
Maravai Q1 2026 slides: 41% revenue surge drives profitability return - Investing.com
Price to book forward of Maravai LifeSciences Holdings, Inc. – NASDAQ:MRVI - TradingView
Millennium Management LLC Reduces Stake in Maravai LifeSciences Holdings Inc - GuruFocus
MRVIMaravai LifeSciences Holdings Inc Volatility & Greeks - Finviz
Maravai LifeSciences stock. Identity holds, but no live catalyst is surfaced. - ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeScience - The National Law Review
Form 4 Maravai Lifesciences Holdings Inc For: 1 July By Investing.com - Investing.com Canada
Maravai (MRVI) CFO has 65,584 shares withheld for RSU tax - Stock Titan
Millennium Management reports >5% stake then falls below 5% in MRVI (MRVI) - Stock Titan
ETFs Investing in Maravai Lifesciences Holdings, Inc. Class A Stocks - TradingView
Price to earnings forward of Maravai Lifesciences Holdings, Inc. Class A – SWB:MAR - TradingView
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronste - The National Law Review
Maravai LifeSciences (MRVI) Investor presentation Summary - Quartr
Maravai Lifesciences Hits New 52-Week High at $5.42 - MarketsMojo
Maravai Lifesciences Hits New 52-Week High of $5.29, Marking Significant Milestone - MarketsMojo
MRVI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Maravai Lifesciences Hits New 52-Week High of $6.21 - MarketsMojo
Price to sales forward of Maravai LifeSciences Holdings, Inc. – NASDAQ:MRVI - TradingView
MAR Forecast — Price Target — Prediction for 2027 - TradingView
Maravai LifeSciences Holdings Inc (MRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to EBIT forward of Maravai LifeSciences Holdings, Inc. – NASDAQ:MRVI - TradingView
Maravai Lifesciences Holdings, Inc. Class A Actuals & Estimates (NASDAQ:MRVI) - TradingView
MRVI Forecast — Price Target — Prediction for 2027 - TradingView
Form 13G Maravai LifeSciences Holdings For: 23 June By Investing.com - Investing.com Australia
Millennium (MRVI) reports 7.32M shared stake, 4.96% as of Jun 16, 2026 - Stock Titan
Maravai LifeSciences Stockanalyst consensus and background snapshot - AD HOC NEWS
Maravai LifeSciences (MRVI) Holds Steady as Shares Consolidate Near Support LevelsFibonacci Retracement - dars.gov.et
Maravai LifeSciences Holdings Inc (MRVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Institutional Confidence - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Maravai LifeSciences Holdings Inc - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maravai LifeSciences (MRVI) Launches New GMP Enzyme Manufacturin - GuruFocus
Maravai LifeSciences Stock (US56600D1072): TriLink opens new GMP enzyme facility in Florida - Ad-hoc-news.de
MRVI PE Ratio & Valuation, Is MRVI Overvalued - Intellectia AI
TriLink Opens GMP Enzyme Manufacturing Facility In Jupiter, Florida - marketscreener.com
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale - Business Wire
Maravai LifeSciences refinances debt with $180M credit facilities; lowers outstanding borrowings - MSN
Maravai LifeSciences Holdings, Inc. (MRVI) tops Q1 earnings and revenue estimates - MSN
Insider Sell: Kurt Oreshack Sells 50,000 Shares of Maravai LifeS - GuruFocus
Maravai LifeSciences general counsel Oreshack sells $253,999 shares By Investing.com - Investing.com Nigeria
Maravai LifeSciences general counsel Oreshack sells $253,999 shares - Investing.com
Maravai Lifesciences Holdings Insider Sold Shares Worth $254,000, According to a Recent SEC Filing - Moomoo
Finanzdaten der Maravai Lifesciences Holdings Inc-Aktie (MRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maravai Lifesciences Holdings Inc-Aktie (MRVI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORESHACK KURT | General Counsel |
Jun 09 '26 |
Sale |
5.06 |
25,000 |
126,500 |
360,767 |
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):